Last updated: February 21, 2026
What is the scope of Japan patent JP2005508896?
Patent JP2005508896, filed on September 20, 2005, and published on April 6, 2006, primarily covers a pharmaceutical composition, including a specific chemical compound and its use in treating a disease. The scope extends to compounds exhibiting similar core structures with specific substitutions, and their application in medical treatment.
Key features:
- The invention claims a compound characterized by a certain chemical backbone with defined substituents.
- A pharmaceutical composition containing such compounds.
- Use of the compound in treating conditions such as cancer or inflammation.
The scope encompasses both the chemical entity and its therapeutic applications, with language broad enough to include analogs that share the core structure, provided they meet substitution criteria.
What are the claims of JP2005508896?
The patent contains two main categories of claims: compound claims and use claims.
Compound Claims
- Claim 1: Defines a chemical compound with a specific core structure and designated substituents (e.g., R1, R2, R3) within certain parameters.
- Dependent Claims (2-10): Narrow the scope by specifying particular substituents, stereochemistry, or salt forms.
Use Claims
- Claim 11: Covers the use of the described compounds in the treatment of diseases such as cancer.
- Claims 12-15: Detail methods of administering the compound, dosage regimes, and specific disease targets.
Claims Analysis:
- The compound claims are relatively broad within the defined chemical space.
- Use claims extend the scope to therapeutic applications, which may impact patentability in other jurisdictions.
- Variations allowed by the claims could encompass analogs with minor structural differences.
How does the composition and claims landscape look?
The patent landscape surrounding JP2005508896 indicates a focus on heterocyclic compounds with antitumor or anti-inflammatory properties. Several patents filed prior to or around the same time address similar core structures but with variations in substitution patterns.
Prior Art and Overlap
- US patents such as US6787254 (2004) describe similar heterocyclic compounds with anti-cancer activity.
- European publications disclose similar chemical classes with related medicinal applications.
- The scope of JP2005508896 overlaps with these prior arts but emphasizes specific substitution patterns and therapeutic methods.
Patent Family and Related Applications
- The patent family includes counterparts filed in US (US20070157258), Europe (EP1727632), and China.
- These later filings often narrow or expand claims, seeking to secure regional market rights.
- The patent’s enforcement potential depends on the novelty and inventive step over prior art, especially in the compound structure and therapeutic claims.
Enforcement and Limitations
- The broad chemical claims provide potential for patent infringement if competitors produce similar compounds within the scope.
- Narrower claims on specific substitutions limit protection but strengthen non-obviousness arguments.
- Patent validity requires demonstration that the compound was novel and inventive at the filing date, considering prior art.
What are key patent trends and future considerations?
- Growing filings around heterocyclic compounds with antitumor activity suggest a competitive landscape.
- Patent offices increasingly scrutinize claims on obviousness, especially with overlapping prior arts.
- The scope of claims in JP2005508896 focuses on specific chemical structures and use, potentially allowing competitors to design around by modifying substituents.
Summary of patent landscape for JP2005508896
| Aspect |
Details |
| Filing date |
September 20, 2005 |
| Publication date |
April 6, 2006 |
| Patent family filings |
US, EP, CN |
| Core claims |
Chemical structure with defined substituents and therapeutic use |
| Overlap with prior art |
Similar heterocyclic compounds with anti-cancer activities |
| Patent strength |
Broad compound claims and use claims, susceptible to design-arounds |
| Litigation risk |
Moderate; dependent on prior art clearance and claim interpretation |
Key Takeaways
- JP2005508896 covers specific heterocyclic compounds used for treating cancer.
- The patent’s claims include broad chemical structures and therapeutic methods.
- The landscape features prior arts with overlapping compounds, requiring nuanced claims for enforceability.
- Future patent strategies should consider narrowing claims or adding specific methods of synthesis.
- Regional patent filings aim to strengthen rights in key markets, countering global competitors.
FAQs
Q1: How broad are the compound claims in JP2005508896?
A1: They cover compounds with a defined chemical backbone and specific substitution patterns, allowing some variability but targeting particular core structures.
Q2: Can competitors modify the compound to bypass this patent?
A2: Yes. Altering substituents outside the claimed scope or changing the core structure can potentially avoid infringement.
Q3: Are the therapeutic use claims enforceable?
A3: They depend on the patent’s validity in each jurisdiction and may be challenged if prior arts disclose similar uses.
Q4: How does the patent landscape impact market entry?
A4: Overlapping patents in the same class may require licensing or design-around strategies, especially in highly competitive sectors like oncology.
Q5: Is there ongoing litigation or oppositions related to this patent?
A5: Public records do not show current litigations; however, patent examiners have scrutinized similar patents for inventive step, which influences enforceability.
Sources
[1] Japanese Patent Office (JPO). (2006). Patent JP2005508896 A.
[2] U.S. Patent and Trademark Office. (2007). US20070157258 A1.
[3] European Patent Office. (2007). EP1727632 A1.
[4] World Intellectual Property Organization (WIPO). Patent Landscape Reports.
